RepliCel Announces Stock Option Grant

RepliCel Announces Stock Option Grant 
VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 09/06/13 -- RepliCel
Life Sciences Inc. (OTCBB:REPCF)(CNSX:RP), a clinical stage
biopharmaceutical company focused on the development of autologous
cell therapies, announces that pursuant to its Stock Option Plan, the
Company granted 1,310,000 options to various employees and
consultants of the Company. The options vest over a three year period
and are exercisable at $0.55 per share until September 5, 2020. 
About RepliCel Life Sciences 
RepliCel is a clinical stage biopharmaceutical company focused on
developing autologous cell therapies. RepliCel Hair-01 (RCH-01) is a
cellular treatment for androgenetic alopecia (pattern baldness).
Shiseido Company, Limited has an exclusive geographic license for
RCH-01 in certain Asian countries including Japan, China and South
Korea. RepliCel Tendon-01 (RCT-01) is a cell therapy for the
treatment of chronic tendon injuries. Both product candidates are
based on RepliCel's innovative technology which utilizes cells
isolated from a patient's own healthy hair follicles to address
specific cellular deficits. Phase II clinical trials, for both
programs, are planned for the later part of 2013. For additional
information please visit  
Notice Regarding Forward Looking Statements  
This press release contains projections and forward-looking
statements, as that term is defined under applicable securities laws.
Statements in this press release, which are not purely historical,
are forward-looking statements that relate to the approval and
commercialization of the Company's hair restoration process, the
Company's development of its Achilles tendon technology and the
expected commencement of the Company's Phase II clinical trial for
its tendon technology. These statements are only predictions and
involve known and unknown risks which may cause actual results and
the Company's plans and objectives to differ materially from those
expressed in the forward-looking information, including: negative
results from the Company's clinical trials; the effects of government
regulation on the Company's business; risks associated with the
Company's ability to obtain and protect rights to its intellectual
property; risks and uncertainties associated with the Company's
ability to raise additional capital; and other factors beyond the
Company's control. Although the Company believes that the
expectations reflected in the forward-looking statements are
reasonable, it cannot guarantee future results, levels of activity or
performance. Further, any forward-looking statement speaks only as of
the date on which such statement is made, and, except as required by
applicable law, the Company undertakes no obligation to update any
forward-looking statement to reflect events or circumstances after
the date on which such statement is made or to reflect the occurrence
of unanticipated events. New factors emerge from time to time, and it
is not possible for management to predict all of such factors and to
assess in advance the impact of such factors on the Company's
business or the extent to which any factor, or combination of
factors, may cause actual results to differ materially from those
contained in any forward-looking statement. Readers should consult
all of the information set forth herein and should also refer to the
risk factor disclosure outlined in the Company's annual report on
Form 20-F for the fiscal year ended December 31, 2012 and other
periodic reports filed from time-to-time with the Securities and
Exchange Commission on Edgar at and with the British
Columbia Securities Commission on Sedar at
Tammey George
Director of Communications
RepliCel Life Sciences
Westwicke Partners, LLC
Stefan Loren, Ph.D.
Managing Director
(443) 213-0507 
Robert H. Uhl
Managing Director
(858) 356-5932
Press spacebar to pause and continue. Press esc to stop.